Skip to main content
MedPathMedPath Home
Clinical Trials/CTRI/2023/12/060500
CTRI/2023/12/060500
Recruiting
未知

Feasibility of Oto-acoustic Emission assessment in identification of ototoxic hearing loss in adult individuals with cancer receiving Cisplatin based Chemo-radiotherapy. - Nil

Tata Research Administrative Council0 sites0 target enrollmentTBD
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
ConditionsHealth Condition 1: C00-C14- Malignant neoplasms of lip, oral cavity and pharynx

Overview

Phase
未知
Intervention
Not specified
Conditions
Health Condition 1: C00-C14- Malignant neoplasms of lip, oral cavity and pharynx
Sponsor
Tata Research Administrative Council
Status
Recruiting
Last Updated
last year
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
last year
Study Type
Observational

Investigators

Sponsor
Tata Research Administrative Council

Eligibility Criteria

Inclusion Criteria

  • •Following are the inclusion criteria for enrollment of the study participants.
  • •1\-Head\-neck cancer patients who are planned to receive Cisplatin\-based definitive or adjuvant chemo\-radiotherapy
  • •2\-Head\-neck cancer patients who are able to provide consistent and reliable responses in conventional pure\-tone audiometry.
  • •3\-Head\-neck cancer patients who have not received any known ototoxic cancer treatment before.
  • •4\-Head\-neck cancer patients without any known cognitive or psychological problems

Exclusion Criteria

  • •Following ear\-wise exclusion criteria at the time of enrollment will be taken for the study.
  • •1\-Ears of Head\-neck cancer patients with air Conduction Hearing thresholds \>50dBHL at any of the octave\-band test frequencies between 0\.5 to 8 KHz.
  • •2\-Ears of Head\-neck cancer patients with Distortion Product Oto\-acoustic Emission (DPOAE)Signal to Noise Ratio (SNR) level \< 6 dBSPL and/ or absolute DPOAE amplitude \< \-10dBSPL at any two test frequencies between 1\.5 to 6KHz
  • •3\-Ears of Head\-neck cancer patients with presence of any Conductive hearing loss at baseline or at end\-of\-treatment evaluation.
  • •4\-Ears of Head\-neck cancer patients with a history of previous ear surgery
  • •5\-Ears of Head\-neck cancer patients with any known pre\-treatment hearing loss documented in baseline audiogram.

Outcomes

Primary Outcomes

Not specified

Similar Trials

Recruiting
Not Applicable
Checking the feasibility of a new hearing assessment tool(Oto-acoustic Emission) in identifying early and significant amount of hearing loss caused due to Cisplatin (widely used as a chemotherapy drug in cancer patients) chemotherapy in pediatric cancer patients.
CTRI/2023/03/051221Tata Research Administrative Council
Not yet recruiting
Not Applicable
comparision of OAE and BERA hearing test as a screening of hearing loss in children (12 year)Health Condition 1: 4- Measurement and Monitoring
CTRI/2022/07/043853Department of Otorhinolaryngology
Active, not recruiting
Not Applicable
Timed acoustic stimulation of sleep in relapsing-remitting multiple sclerosis
ISRCTN11468655niversity of Bristol12
Completed
Not Applicable
*Sound-Ear-Check*: analysis and validation of screening tests for hearing using non-speech sounds in noise.
NL-OMON43325Academisch Medisch Centrum104
Not yet recruiting
Not Applicable
Study of neonatal screening for hearing loss using otoacoustic emissions
CTRI/2023/07/055805Jagjivan Ram Railway Hospital